Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03603405 · ClinicalTrials.gov registry record · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
A Phase 1 study of Glioblastoma and Anaplastic Astrocytoma, sponsored by The Methodist Hospital Research Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT03603405 is a Phase 1 study of Glioblastoma and Anaplastic Astrocytoma that is actively recruiting participants, run by The Methodist Hospital Research Institute. The registered enrollment target is 62 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03603405, a Phase 1 study of Glioblastoma and Anaplastic Astrocytoma, is actively recruiting participants, sponsored by The Methodist Hospital Research Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).
Conditions Studied
Interventions
- DRUG ADV/HSV-tk (gene therapy)
Study Locations (1)
Texas
- Houston Methodist Neurological Institute - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2018-02-28 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03603405
The ClinicalTrials.gov registry entry for NCT03603405 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (43% lower). The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which ADV/HSV-tk (gene therapy) is the first listed.
NCT03603405 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03603405 about?
NCT03603405 is a clinical study titled "HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM". Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).
What is the current status of trial NCT03603405?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2018-02-28. Estimated completion is 2025-12-31.
What conditions does trial NCT03603405 study?
This clinical trial studies the following conditions: Glioblastoma, Anaplastic Astrocytoma.
What interventions are being tested in trial NCT03603405?
The interventions under investigation include: ADV/HSV-tk (gene therapy) (DRUG).
Who is sponsoring clinical trial NCT03603405?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03603405 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.